Appointments

Meenu brings with her over 20 years of experience in the global biopharmaceutical industry from leadership roles in both private and public large pharmaceutical companies and smaller biotech companies.

Since July 2023, Meenu has been executive chairperson of Samsara Therapeutics, and a member of the board of Macrogenics and its audit committee since January 2023.

Jan Thirkettle, chief executive officer of Harness Therapeutics, stated: “I am delighted to welcome Meenu as our new board chair. Her strategic leadership, company building and wide business development expertise, will enhance our efforts to open up the target space for neurodegenerative diseases. Meenu joins the company at an important time as we advance our lead Huntington’s disease programme towards the clinic and seek to broaden our portfolio based on the platform we have established over the past three years.”

Commenting on her new role, Meenu stated: “I am truly excited to be appointed as chair of Harness Therapeutics. I believe my capabilities and experience can help advance the company and leverage our lead Huntington’s disease programme. With a unique approach to controlled up-regulation of CNS targets we have the potential to transform the treatment of not only Huntington’s disease but potentially a broad array of neurodegenerative diseases for the benefit of patients worldwide.”